Future of PV Treatments Centers Around More Tailored Approaches

[Manouche]

“Treatment of patients with PV should be, in my opinion, tailored based on the risk,” Francesco Passamonti, MD, said in his presentation at the Society of Hematology Oncology 2021 Annual Conference. “This is quite important. In the future, we will probably have to work more on additional mutations and the role of additional mutations in the prediction of events in PV.”

onclive.com/view/future-of-...

[MPort]

Thank you. More hope.

[Meatloaf9]

Hi, as a PV patient I sincerely appreciate your posts on treatments and advances in the care of MPN patients. Hope you are doing well and thanks again for keeping us all informed. Best.

[dishcell]

Thank you very interesting.

[Aneliv9]

PV has 34% rate of progression to MF at 10 years?????

[Manouche in reply to Aneliv9]

On some cohorts of « phlebotomy only »patients.

[Aneliv9 in reply to Manouche]

Why this group has more chances of progression?

[cmc_ufl in reply to Aneliv9]

PV is generally regarded to be a less stable disease than ET since multiple cell lineages (erythrocytes and often thrombocytes) are affected. This puts the bone marrow under a higher degree of stress, which increases the risk of MF.